Up to Mar 31, there were 79 cases of people developing blood clots having received an AstraZeneca vaccine. Of those, 19 died
Citing reviews from the United Kingdom Medicines and Healthcare Products Regulatory Agency and European Medicines Agency, AstraZeneca said yesterday that its COVID-19 vaccines offer “high level of protection” against the virus.
The intense public scrutiny is vaccine safety at work.
There are Insider's top healthcare stories for the week ending March 26.
New South Wales has suspended AstraZeneca vaccinations for all age groups over the jabs link to a rare blood clot condition after health authorities advised it not be given to anyone under 50.
People in the UK under 30 will be offered an alternative to the AstraZeneca vaccine because of a possible link to rare blood clots. Could the move dent confidence in the widely used jab?
After a UK recommendation that healthy adults under 30 should have an alternative jab, here’s the latest information and adviceCoronavirus – latest updatesSee all our coronavirus coverageConcerns have been mounting over reports of rare but serious blood clots in a small number of recipients of the Oxford/AstraZeneca vaccine, leading to a UK recommendation on Wednesday that healthy adults under 30 should have an alternative jab if they can. We take a look at the latest information and guidance....
The United States recently surpassed 550,000 deaths attributed to COVID-19. This is more lives lost than in World War I, World War II and the Vietnam War combined. Fortunately, things are improving. COVID-19 infections and deaths have decreased considerably over the past few months. According to the COVID-19 Hospitalization Tracking
Here MailOnline answers all of your questions about AstraZeneca's jab, revealing why it is safe for you to still get your second dose and what the alternatives are for under-30s.
These are Insider's biggest healthcare stories for April 1.
Updated recommendations come amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000.
Canada is suspending the use of the Oxford-AstraZeneca vaccine for people under the age of 55 following concerns it may be linked to rare blood clots